Pan-Cancer Analysis of the Prognostic and Immunological Role of SMG5: A Biomarker for Cancers.
| Autor: | Yang, Leteng, Wei, Jie, Ma, Xiaoya, Cheng, Rui, Zhang, Huan, Jin, Tianbo |
|---|---|
| Předmět: |
CANCER cell culture
CELL differentiation PREDICTIVE tests IMMUNE checkpoint proteins CARCINOGENESIS GLIOMAS REGRESSION analysis NEOPLASTIC cell transformation CELL physiology GENOTYPES SURVIVAL analysis (Biometry) KAPLAN-Meier estimator TUMOR markers CELL lines SENSITIVITY & specificity (Statistics) PROPORTIONAL hazards models ALGORITHMS CARRIER proteins |
| Zdroj: | Oncology; 2024, Vol. 102 Issue 2, p168-182, 15p |
| Abstrakt: | Introduction:SMG5 is involved in tumor cell development and viewed as a potential target for immunotherapy. The purpose of this study was to systematically analyze the expression level, function, and prognostic value of SMG5 in pan-cancers. Methods: Differential expression of SMG5 in normal and tumor tissues was analyzed using The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression Database (GTEx) data. Survival analysis was performed by Kaplan-Meier method and Cox risk regression. The relationship between SMG5 expression and lymphocyte abundance, tumor cell immune infiltration level, molecular and immune subtypes as well as immune checkpoints was analyzed by tumor-immune system interactions database (TISIDB), Tumor Immune Estimation Resource (TIMER), and Sangerbox databases. The correlation between SMG5 and immune scores was studied using the Estimation of Stromal and Immune Cells in Malignant Tumours using Expression (ESTIMATE) data algorithm. Further, drug sensitivity analysis of SMG5 with low-grade glioma (LGG) was conducted using the CellMiner database. Results:SMG5 was highly expressed in 23 tumors and only had a significant impact on the prognosis of patients with LGG only. In addition, in tumor microenvironment and tumor immune analysis, we found that the level of immune infiltration, tumor mutational load, microsatellite instability, and immune checkpoints of LGG were significantly correlated with SMG5 expression. Furthermore, SMG5 was significantly associated with immune scores, stromal scores, and sensitivity of some drugs in LGG. Conclusion:SMG5 is differentially expressed in several cancers and is significantly associated with prognosis, immune microenvironment, and immune checkpoints in LGG patients. Therefore, SMG5 could be a potential pan-cancer biomarker and an immunotherapeutic target for LGG. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|